SOURCE: Proove Biosciences, Inc.

Proove Biosciences, Inc.

August 17, 2016 12:22 ET

Proove Biosciences Named One of America's Fastest-Growing Private Companies on 2016 Inc. 500 List

Innovative Big Data Genetics Company Joins Roster of Distinguished High-Growth Organizations

IRVINE, CA--(Marketwired - Aug 17, 2016) - Proove Biosciences, Inc. -- the Healthcare Decision Company™ -- is an industry pioneer in the convergence of molecular diagnostics and big data through a patented bioinformatics platform, which combines genetic and clinical data to deliver information that helps healthcare decision-makers individualize and improve treatment outcomes. This dynamic company, which is revolutionizing the approach to managing and treating chronic pain, is excited to announce that it has been awarded a spot on the 2016 Inc. 500 list -- a distinction that recognizes the fastest-growing private companies in America. Inc. Magazine's annual list is considered the gold standard for highlighting the 500 U.S. companies that are generating the highest sales growth on a percentage basis.

"To be ranked 323 out of approximately 18,000,000 businesses in America is an incredible honor for the nearly 300 employees at Proove who are working tirelessly to make a difference in the world," says Proove founder and CEO, Brian Meshkin. "From Proove's inception, our mission has been focused on improving the quality of life of patients who are affected by our nation's largest and most expensive health condition -- pain. By delivering a portfolio of unique profiles that help physicians deliver patients with the finest health care experience, we are more than just a business -- we are doing our part to contribute to a healthier society." Proove's technologically-advanced suite of products addresses many common problems associated with pain, assesses serious issues surrounding dosing and addiction to opioid and prescription medication, and evaluates the effectiveness of treatment alternatives.

"Pain is a major problem across the country and it affects more Americans and costs our society more than cancer, diabetes, and heart disease combined," adds Meshkin. "Our goal is to inform physicians, payers, policy makers, and the public that there is a better way to assess pain rather than using a subjective 1-10 scale. Within this context, there is a better way to choose medications and avoid the dangers of opioid abuse. That better way is Proove -- and being added to the elite Inc. 500 only furthers that cause."

By using its advanced bioinformatics platform, Proove is able to combine genetic and clinical data to create easy-to-understand profiles to empower physicians and patients to better manage conditions based on objective and predictive information, thereby reducing reliance on "trial-and-error" approaches to medication selection and dosing. The company has grown from three employees and 150 tests in 2011 to more than 200,000 tests and 250 employees in 2016 -- and is poised to continue its exceptional growth trajectory.

Proove Biosciences will be honored for its inclusion on the respected list of companies at the Oct. 18-20, 2016 35th Annual Inc. 5000 Conference and Gala, held at the JW Marriott Hill Country in San Antonio, TX

For more information, please visit: http://www.inc.com/inc5000.

To learn more about Proove Biosciences, visit www.proove.com. With media inquiries, please contact Leslie Licano at leslie@beyondfifteen.com or (949)-733-8679.

About Proove Biosciences
Proove Biosciences -- the Healthcare Decision Company™ -- is the commercial and educational leader in the research, investigation and development of patent-protected tests that combine genetic and clinical data into reports to help physicians to individualize -- and optimize -- medicine selection and dosing. Supported by leading medical experts and institutions across the globe, the reports facilitate objective decision-making to improve outcomes for patients, providers and insurers. Backed by science and driven by data, Proove is revolutionizing individualized medicine. With a patented bioinformatics platform that delivers therapy-defining information that allows prescribers to evaluate pain tolerance, identify risk for dependence and addiction, predict response and immunity to opioid and non-opioid pain medication, and assess patient drug metabolism, Proove provides the most technologically advanced solutions to enable accurate and evidence-based medical decision-making rather than "trial-and-error" approaches. Proove helps reduce the risk of treatment failure, decrease costs to insurers and relieve society of the emotional and financial burdens associated with addiction and other avoidable consequences. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Contact Information